GLP-1 users are exercising less People taking GLP-1 medications for weight loss are moving less after they start the drugs, according to a study being presented at the Endocrine Societys Annual Meeting
Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging
The turning point came around 2015, when higher-dose liraglutide, under the brand name Saxenda, was approved for obesity, confirming the weight loss effect wasnt just a side effect, but a primary therapeutic action. GLP-1s worked differently from earlier diet drugs
For chronic conditions like type 2 diabetes, heart disease, or kidney decline, Ozempic is often a long-term or even lifelong treatment
Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for practical volume measurements